Compare Amgen, Inc. (AMGN) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Halliburton Company — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Halliburton Company trades at $34.75 (market cap $28.73B). The key difference: Amgen, Inc. is far larger — about 6.8× Halliburton Company's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | HAL | |
|---|---|---|
Market Cap | $196.12B | $28.73B |
Sector | Health | Energy |
52-Week High | $388.16 | $42.98 |
52-Week Low | $271.18 | $20.50 |
Enterprise Value | $241.41B | $34.81B |
Dividend Yield | 2.77% | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Halliburton (HAL) trades at $34.39, up 0.79% with a bullish technical signal. The company shows solid fundamentals with a P/E of 19 and ROE of 14.56%, though recent earnings beat expectations with Q1 2026 EPS of $0.55 versus $0.50 expected. Recent developments include a key Iraq oilfield deal and digital transformation partnerships, supporting growth prospects in the oil services sector.
Outlook remains positive with analyst consensus price target of $44.00 (28% upside), though risks include oil price volatility and execution challenges. Revenue stability around $22B and strong cash flow generation provide fundamental support, while technical indicators suggest potential resistance near $35.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
